Stage IVB Lung Cancer AJCC v8 Recruiting Phase 2 Trials for Brigatinib (DB12267)

IndicationStatusPhase
DBCOND0111251 (Stage IVB Lung Cancer AJCC v8)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03737994Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTreatment